2023
Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53
Siddon A, Weinberg O. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics In Laboratory Medicine 2023, 43: 607-614. PMID: 37865506, DOI: 10.1016/j.cll.2023.07.004.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyelodysplastic syndromeTP53 mutationsPrognosis of MDSCases of MDSPrognostic scoring systemNext-generation sequencingParticular next-generation sequencingAggressive diseasePoor outcomeTherapeutic managementTP53 disruptionMyeloid leukemiaMyeloid neoplasmsTherapeutic advancementsCytogenetic abnormalitiesMyeloid neoplasiaScoring systemDisease classificationMyeloid diseasesGene mutationsSyndromeDiseaseDiagnosisTP53Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes
Mendoza H, Siddon A. Molecular Techniques and Gene Mutations in Myelodysplastic Syndromes. Clinics In Laboratory Medicine 2023, 43: 549-563. PMID: 37865502, DOI: 10.1016/j.cll.2023.06.002.Peer-Reviewed Original ResearchMolecular findings in myeloid neoplasms
Tran T, Siddon A. Molecular findings in myeloid neoplasms. International Journal Of Laboratory Hematology 2023, 45: 442-448. PMID: 37345257, DOI: 10.1111/ijlh.14118.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid neoplasmsNext-generation sequencingMyeloproliferative neoplasmsInternational diagnostic guidelinesSomatic gene mutationsHematologic cancersMyeloid leukemiaDiagnostic guidelinesClinical relevanceMyeloid disordersPatient careNeoplasmsCytogenetic findingsMolecular findingsGene mutationsNew molecular technologiesMolecular technologiesMutationsLeukemiaCancerPrognosticationCliniciansFindingsModifier mutationsOptimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative threshold
2020
The utility and limitations of B- and T-cell gene rearrangement studies in evaluating lymphoproliferative disorders
Mendoza H, Tormey CA, Rinder HM, Howe JG, Siddon AJ. The utility and limitations of B- and T-cell gene rearrangement studies in evaluating lymphoproliferative disorders. Pathology 2020, 53: 157-165. PMID: 33358756, DOI: 10.1016/j.pathol.2020.09.024.Peer-Reviewed Original ResearchConceptsTCR gene rearrangement analysisGene rearrangement analysisPolymerase chain reactionRearrangement analysisLymphocyte populationsLymphoid malignanciesT-cell receptor gene rearrangement analysisT-cell gene rearrangement studiesTCR gene rearrangement patternsT cell populationsGene rearrangement studiesNext-generation sequencingGene rearrangement patternsLymphoproliferative disordersCriteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost
Gisriel S, Rinder H, Siddon A. Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost. Blood 2020, 136: 39-40. DOI: 10.1182/blood-2020-139035.Peer-Reviewed Original ResearchNext-generation sequencingNGS testingNGS testsAML/MDSEvidence-based indicationsPatients' emotional distressCancellation criteriaMedicaid Services reimbursementPersonalized patient careClinical suspicionPathologic diagnosisMedical recordsClinical indicationsClinical trialsChimerism statusUnnecessary testingMDS progressionPatient carePathogenic variantsMolecular findingsUnknown significancePatientsPathogenic mutationsService reimbursementMolecular diagnostic laboratoriesImpact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival
Schulz WL, Rinder HM, Durant TJS, Tormey CA, Torres R, Smith BR, Hager KM, Howe JG, Siddon AJ. Impact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival. Leukemia & Lymphoma 2020, 61: 3269-3271. PMID: 32715805, DOI: 10.1080/10428194.2020.1797016.Peer-Reviewed Original Research
2015
Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia
Schulz W, Durant T, Rinder H, Tormey C, Torres R, Smith B, Hager K, Howe J, Siddon A. Impact of Molecular Clonality on Survival in Acute Myeloid Leukemia. Blood 2015, 126: 1385. DOI: 10.1182/blood.v126.23.1385.1385.Peer-Reviewed Original ResearchDe novo acute myeloid leukemiaNovo acute myeloid leukemiaAcute myeloid leukemiaMolecular clonalityAML patientsTumor heterogeneityMyeloid leukemiaNext-generation sequencingNormal-risk subjectsAdverse prognostic indicatorTime of diagnosisFurther prospective studiesLong-term outcomesFLT3-ITD mutationHigh-risk groupChoice of therapyFirst prospective evidenceLimited clinical utilityHigh-risk classificationEarly survivalStudy patientsOverall survivalPatient agePatient subsetsInitial diagnosis